Weng Wenhao, Wei Qing, Toden Shusuke, Yoshida Kazuhiro, Nagasaka Takeshi, Fujiwara Toshiyoshi, Cai Sanjun, Qin Huanlong, Ma Yanlei, Goel Ajay
Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.
Department of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Clin Cancer Res. 2017 Jul 15;23(14):3918-3928. doi: 10.1158/1078-0432.CCR-16-2541. Epub 2017 Feb 7.
Colorectal cancer is one of the most common malignancies worldwide. Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As miR-7, a putative tumor-suppressor, regulates the expression of several important drivers of colorectal cancer, we analyzed the clinical significance of ciRS-7 in colorectal cancer patients. Initially, we evaluated the expression levels of ciRS-7 in a training cohort comprising of 153 primary colorectal cancer tissues and 44 matched normal mucosae. We subsequently confirmed its clinical relevance in an independent validation cohort ( = 165), and evaluated the effect of ciRS-7 on miR-7, and its target genes EGFR and RAF1. Functional analyses were performed in cell lines and an animal model to support clinical findings. Our data revealed that ciRS-7 was significantly upregulated in colorectal cancer tissues compared with matched normal mucosae ( = 0.0018), and its overexpression was associated with poor patient survival ( = 0.0224 and 0.0061 in the training and validation cohorts, respectively). Multivariate survival analysis revealed that ciRS-7 emerged as an independent risk factor for overall survival ( = 0.0656 and 0.0324 in the training and validation cohorts, respectively). Overexpression of ciRS-7 in HCT116 and HT29 cells led to the blocking of miR-7 and resulted in a more aggressive oncogenic phenotype, and ciRS-7 overexpression permitted the inhibition of miR-7 and subsequent activation of EGFR and RAF1 oncogenes. CiRS-7 is a promising prognostic biomarker in colorectal cancer patients and may serve as a therapeutic target for reducing EGFR-RAF1 activity in colorectal cancer patients. .
结直肠癌是全球最常见的恶性肿瘤之一。最近,一种新型环状RNA,即ciRS-7,被认为是一种潜在的miR-7海绵。由于miR-7作为一种假定的肿瘤抑制因子,可调节结直肠癌的几个重要驱动因子的表达,我们分析了ciRS-7在结直肠癌患者中的临床意义。首先,我们在一个由153个原发性结直肠癌组织和44个匹配的正常黏膜组成的训练队列中评估了ciRS-7的表达水平。随后,我们在一个独立的验证队列(n = 165)中证实了其临床相关性,并评估了ciRS-7对miR-7及其靶基因EGFR和RAF1的影响。在细胞系和动物模型中进行了功能分析以支持临床研究结果。我们的数据显示,与匹配的正常黏膜相比,ciRS-7在结直肠癌组织中显著上调(P = 0.0018),其过表达与患者生存不良相关(在训练队列和验证队列中分别为P = 0.0224和0.0061)。多因素生存分析显示,ciRS-7成为总生存的独立危险因素(在训练队列和验证队列中分别为P = 0.0656和0.0324)。ciRS-7在HCT116和HT29细胞中的过表达导致miR-7的阻断,并导致更具侵袭性的致癌表型,并且ciRS-7过表达允许miR-7的抑制以及随后EGFR和RAF1致癌基因的激活。CiRS-7是结直肠癌患者中有前景的预后生物标志物,并且可能作为降低结直肠癌患者中EGFR-RAF1活性的治疗靶点。